Predicting the Risk of Cardiovascular Comorbidities in Adult Cancer Survivors

Tashakkor, A. Yashar; Moghaddamjou, Ali; Chen, L.; Cheung, Winson Y.

doi:10.3747/co.20.1470

Cited by 24 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The risk of cardiovascular‐related death also was 3‐fold greater for patients with follicular lymphoma who were diagnosed with CHF. Anthracyclines and preexisting hypertension and diabetes were found to be the major risk factors for the development of new‐onset CHF, providing evidence of the need to institute aggressive measures to manage these cardiovascular risk factors to reduce the risk of CHF among patients with follicular lymphoma …”

Section: Discussionmentioning

confidence: 99%

Congestive heart failure in older adults diagnosed with follicular lymphoma: A population‐based study

Kenzik

Mehta

Richman

et al. 2018

Cancer

View full text Add to dashboard Cite

Background To the authors’ knowledge, there is limited information regarding the long‐term risk of congestive heart failure (CHF) among patients with follicular lymphoma, a prevalent non‐Hodgkin lymphoma diagnosis among those aged >65 years, especially within the context of therapeutic exposures and preexisting comorbidities. Methods Using Surveillance, Epidemiology, and End Results–Medicare data from 1999 through 2013, the authors identified 6109 patients with follicular lymphoma who were diagnosed at age ≥66 years between January 1, 2000 and December 31, 2011, and a frequency‐matched Medicare noncancer sample. Subdistribution hazards models assessed risks associated with new‐onset CHF through December 31, 2013. Propensity score–matched models examined CHF risk in patients receiving anthracyclines when compared with matched noncancer controls. Results When compared with matched controls, patients with follicular lymphoma receiving anthracyclines at ages 66 to 75 years had a 1.7‐fold (95% confidence interval, 1.4‐fold to 2.1‐fold) higher risk of new‐onset CHF; patients diagnosed at age >75 years did not differ from noncancer controls with regard to CHF risk. Preexisting hypertension was associated with a 1.7‐fold and 1.35‐fold, respectively, increased hazard of CHF for each age group, independent of anthracycline exposure. Preexisting diabetes was associated with 1.5‐fold increased hazard of CHF only in those patients aged 66 to 75 years. Patients with new‐onset CHF had a 18% lower 10‐year survival compared with those without CHF. Conclusions Patients with follicular lymphoma who were exposed to anthracyclines between the ages of 66 years and 75 years were found to be at an increased risk of new‐onset CHF; preexisting hypertension and diabetes appeared to increase this risk. The findings of the current study support and inform the risk‐based follow‐up of vulnerable populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Congestive heart failure in older adults diagnosed with follicular lymphoma: A population‐based study

Kenzik

Mehta

Richman

et al. 2018

Cancer

View full text Add to dashboard Cite

show abstract

“…Similarly, in cancer patents the pleiotropic activity of drugs used for dyslipidaemia and optimal lipid profile control may be crucial for preventing a marked rise in CV risk, for example in patients who have completed chemotherapy [152]. …”

Section: Treatment Of Lipid Disorders In Selected Populationsmentioning

confidence: 99%

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016

Banach¹,

Jankowski²,

Jóźwiak³

et al. 2017

aoms

145

View full text Add to dashboard Cite

“…Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide 1 . Regrettably, cardiovascular disease (CVD) has risen in the aftermath as one of the most devastating consequences of cancer therapies 2 , 3 , being most prevalent in adult survivors of breast cancer and hematological malignancies 1 , 4 , 5 .…”

Section: Introductionmentioning

confidence: 99%

Protecting the heart in cancer therapy

Finet¹,

Tang²

2018

F1000Res

View full text Add to dashboard Cite

Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide. Regrettably, cardiovascular disease has risen in the aftermath as one of the most devastating consequences of cancer therapies. In this work, we define cancer therapeutics-induced cardiotoxicity as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies. We describe four progressive stages of this condition and four corresponding levels of prevention, each having a specific goal, focus, and means of action. We subsequently unfold this didactic framework, surveying mechanisms of cardiotoxicity, risk factors, cardioprotectants, biomarkers, and diagnostic imaging modalities. Finally, we outline the most current evidence-based recommendations in this area according to multidisciplinary expert consensus guidelines.

show abstract

Predicting the Risk of Cardiovascular Comorbidities in Adult Cancer Survivors

Abstract: ConClusionsIndependent risk factors for ihd and chf in css were identified. The risk stratification schema presented here may be helpful in developing a risk-based approach to preventive cardiovascular strategies for css.

Cited by 24 publications

References 22 publications

Congestive heart failure in older adults diagnosed with follicular lymphoma: A population‐based study

Congestive heart failure in older adults diagnosed with follicular lymphoma: A population‐based study

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016

Protecting the heart in cancer therapy

Contact Info

Product

Resources

About